Luke Sergott

Q: What is Luke Sergott's success rate?

Luke Sergott currently has a success rate of 99.56896551724138.

Q: What is the average return of Luke Sergott's calls?

Their stock ratings have generated an average return of 12.661044569994788.

Barclays | Healthcare

Luke Sergott is an analyst from Barclays specializing in the Healthcare sector. Ranked #1089 out of 4565 analysts, they have issued 121 stock ratings with a success rate of 99.57% and an average return of 12.66%.

Luke Sergott has a well-established track record, with 121 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 99.57% and an average return of 12.66%, underscoring their expertise and ability to identify winning opportunities for investors.

#1089

Out of 4565

121

Total Ratings

+99.57%

Success Rate

+12.66%

Average Return

Recent Ratings Analysis

PACB

Sell

Mar 06, 2026

Target

$2.00

Current

$1.38

Performance

0.00%

Luke Sergott rated PACB as Underweight on Mar 06, 2026, setting a price target of 2. So far, the bearish outlook hasn’t materialized, with shares flat near 1.38.

MEDP

Hold

Mar 06, 2026

Target

$500.00

Current

$470.59

Performance

0.00%

On Mar 06, 2026, MEDP was given a Equal-Weight rating by Luke Sergott, with a target price of 500. Market indecision, reflected in sideways trading near 470.59, supported the cautious call.

IQV

Buy

Mar 06, 2026

Target

$210.00

Current

$174.49

Performance

0.00%

IQV received a Overweight rating from Luke Sergott on Mar 06, 2026, aiming for 210. Price action was muted, as shares hovered around 174.49 despite the bullish outlook.

CERT

Hold

Mar 06, 2026

Target

$8.00

Current

$7.06

Performance

0.00%

On Mar 06, 2026, Luke Sergott published a Equal-Weight outlook on CERT, with a target of 8. Sideways action left the Hold view intact, with no major move since 7.06.

AVTR

Sell

Mar 06, 2026

Target

$8.50

Current

$8.17

Performance

0.00%

Luke Sergott on Mar 06, 2026 assigned AVTR a Underweight rating, with a price target of 8.5. The bearish stance awaits confirmation while shares hold level at 8.17.

FTRE

Hold

Feb 27, 2026

Target

$15.00

Current

$9.61

Performance

-10.35%

On Feb 27, 2026, Luke Sergott reaffirmed FTRE with a Equal-Weight rating, targeting 15. The Hold stance reflected market caution that was later justified.

A

Buy

Feb 26, 2026

Target

$165.00

Current

$115.07

Performance

-4.88%

A was rated Overweight by Luke Sergott on Feb 26, 2026, with a price objective of 165. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

RGEN

Buy

Feb 25, 2026

Target

$200.00

Current

$119.99

Performance

-9.19%

On Feb 25, 2026, Luke Sergott initiated coverage on RGEN with a Overweight rating and target of 200. The Buy call has yet to be validated as shares remain 80.01 away from the target.

CRL

Buy

Feb 19, 2026

Target

$215.00

Current

$174.46

Performance

6.22%

Luke Sergott issued a Overweight recommendation for CRL on Feb 19, 2026, price target set at 215. Investors following the Buy call captured upside momentum, with shares now at 174.46.

BRKR

Buy

Feb 13, 2026

Target

$55.00

Current

$36.68

Performance

0.47%

On Feb 13, 2026, BRKR was evaluated by Luke Sergott, who gave a Overweight rating and target of 55. So far, the Buy call awaits clearer momentum, with shares flat at 36.68.

WST

Hold

Feb 13, 2026

Target

$325.00

Current

$245.86

Performance

-1.85%

Luke Sergott rated WST as Equal-Weight on Feb 13, 2026, setting a price target of 325. The Hold stance appears justified, as shares hovered around 245.86 with a -1.85% move.

WAT

Buy

Feb 11, 2026

Target

$400.00

Current

$302.54

Performance

-8.10%

On Feb 11, 2026, WAT was given a Overweight rating by Luke Sergott, with a target price of 400. Despite the Buy call, shares fell from 302.54 to 302.54, challenging the optimistic stance.

RVTY

Buy

Feb 03, 2026

Target

$118.00

Current

$91.34

Performance

-9.68%

RVTY received a Overweight rating from Luke Sergott on Feb 03, 2026, aiming for 118. The rating hasn’t played out as hoped, with the stock trading 9.68% below expectations.

TWST

Buy

Feb 03, 2026

Target

$50.00

Current

$46.94

Performance

1.34%

On Feb 03, 2026, Luke Sergott published a Overweight outlook on TWST, with a target of 50. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 46.94.

TMO

Buy

Jan 30, 2026

Target

$650.00

Current

$501.97

Performance

-13.25%

Luke Sergott on Jan 30, 2026 assigned TMO a Overweight rating, with a price target of 650. The call has struggled to gain traction, with shares losing 13.25%.

TXG

Buy

Dec 15, 2025

Target

$22.00

Current

$20.81

Performance

32.04%

On Dec 15, 2025, Luke Sergott reaffirmed TXG with a Overweight rating, targeting 22. The recommendation was supported by strong follow-through as the stock rose from 20.81 to 20.81.

QGEN

Buy

Dec 15, 2025

Target

$55.00

Current

$44.55

Performance

-6.86%

QGEN was rated Overweight by Luke Sergott on Dec 15, 2025, with a price objective of 55. This case shows how bullish projections can fail, with the stock now below 44.55.

NTRA

Buy

Dec 15, 2025

Target

$270.00

Current

$198.13

Performance

-13.25%

On Dec 15, 2025, Luke Sergott initiated coverage on NTRA with a Overweight rating and target of 270. The Buy call has yet to be validated as shares remain 71.87 away from the target.

MTD

Buy

Dec 15, 2025

Target

$1600.00

Current

$1209.65

Performance

-14.36%

Luke Sergott issued a Overweight recommendation for MTD on Dec 15, 2025, price target set at 1600. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

ILMN

Sell

Dec 15, 2025

Target

$110.00

Current

$124.62

Performance

-7.63%

On Dec 15, 2025, ILMN was evaluated by Luke Sergott, who gave a Underweight rating and target of 110. The recommendation was proven wrong by upward action toward 110.

ICLR

Hold

Dec 15, 2025

Target

$200.00

Current

$107.20

Performance

-41.86%

Luke Sergott rated ICLR as Equal-Weight on Dec 15, 2025, setting a price target of 200. The cautious Hold call aligned with subsequent weakness, as shares slipped 41.86%.

GH

Buy

Dec 15, 2025

Target

$120.00

Current

$91.20

Performance

-11.17%

On Dec 15, 2025, GH was given a Overweight rating by Luke Sergott, with a target price of 120. Despite the Buy call, shares fell from 91.2 to 91.2, challenging the optimistic stance.

EXAS

Hold

Nov 21, 2025

Target

$105.00

Current

$103.50

Performance

2.58%

EXAS received a Equal-Weight rating from Luke Sergott on Nov 21, 2025, aiming for 105. Shares remained flat at 103.5, aligning with the neutral rating.

SHC

Buy

Nov 05, 2025

Target

$20.00

Current

$14.66

Performance

-7.27%

On Nov 05, 2025, Luke Sergott published a Overweight outlook on SHC, with a target of 20. Market action contradicted the Buy thesis, as shares slipped to 14.66.

DHR

Buy

Oct 22, 2025

Target

$250.00

Current

$195.50

Performance

-10.36%

Luke Sergott on Oct 22, 2025 assigned DHR a Overweight rating, with a price target of 250. The call has struggled to gain traction, with shares losing 10.36%.

INCY

Buy

Aug 01, 2025

Target

$90.00

Current

$95.94

Performance

26.92%

On Aug 01, 2025, Luke Sergott reaffirmed INCY with a Overweight rating, targeting 90. The recommendation was supported by strong follow-through as the stock rose from 95.94 to 95.94.

CTLT

Hold

Jun 28, 2024

Target

$63.00

Current

$63.48

Performance

12.89%

CTLT was rated Equal-Weight by Luke Sergott on Jun 28, 2024, with a price objective of 63. Despite caution, upside momentum rewarded risk-takers with gains to 63.48.

Frequency Asked Questions

Who is Luke Sergott?

Luke Sergott is an analyst from Barclays specializing in the Healthcare sector.

What is Luke Sergott's success rate?

Luke Sergott currently has a success rate of +99.57%.

How many ratings has Luke Sergott issued?

Luke Sergott has issued 121 stock ratings so far.

What is the average return of Luke Sergott's calls?

Their stock ratings have generated an average return of +12.66%.

What is Luke Sergott's ranking?

Luke Sergott is ranked #1089 out of 4565 analysts.

What types of ratings does Luke Sergott give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Luke Sergott?

You can follow Luke Sergott by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Luke Sergott?

Their latest rating was a Sell on PACB issued on 2026-03-06.